中联品牌怎么样 申请店铺

更新时间:2024-07-14
中联是哪个国家的品牌?「中联」是 国药集团中联药业有限公司 旗下著名品牌。该品牌发源于广东,由创始人蒋焘在1998-04-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
中联怎么样

国药中联有着悠久的历史,由拥有四百余年中医药历史并享誉全国的叶开泰、达仁堂、刘有余堂金同仁、九芝堂、陈太乙等为代表的192家中药店铺联合组建而成。1952年,在原武汉市中药饮片业同业公会的发动下,成立武汉市中联制药厂。1997年股份制改造,2002年成立集团公司,2011年底重组进入中国较大的健康产业平台――中国医药集团。经过60余年发展壮大,公司已形成包括中成药、化学制剂生产和销售、医药商业营运等在内的多种产业结构,成为集科研、生产、流通、外贸于一体的专业医药健康企业。

公司专注经典中药生产与销售。拥有注册产品300余个,有82个品种列入国家基本药物目录,有14个品种,其中战略大品种鳖甲煎丸有两千多年历史,为汉代张仲景经典古方,专治胁下癥块。公司产品涉足肝脏用药、呼吸系统用药、妇科用药、心脑血管用药等特色领域,已形成以鳖甲煎丸为代表的肝脏用药系列,以金叶败毒颗粒、鼻炎片、强力感冒片为代表的呼吸道用药系列,以脉君安片、心脑清软胶囊为代表的心脑血管用药系列,以加味生化颗粒为代表的妇科用药系列。

公司注重经典中药的系统深度开发。依托国药集团旗下中国医药工业研究总院研发平台,广泛开展国内、国际合作与交流,不断探索经典古方治病机理,研究新工艺,保障产品疗效,拥有多项自主知识产权,为公司的可持续发展奠定了坚实地基础。

公司营销网络遍布全国多省、自治区、直辖市,终端销售网点覆盖全国,主要品种出口日本、马来西亚、印尼、美国等国家和地区。公司不仅销售产品,同时专注于将中医药哲学(文化)、产品核心价值传递给医生和患者,使“中联”成为受医生和患者尊重的制药企业,为中国中医药的发展贡献力量。

公司在东湖高新技术开发区光谷生物城按照现代中药生产标准兴建的“中联中医药产业园”已经建成,未来,公司将以此为依托,以“挖掘传承创新发扬中国中药,为‘家人’提供经典好中药”为已任,传承发扬中国中药,力争成为国内优秀现代化中药企业。十三五末营业收入过十亿元,利润过亿元。


Sinopharm has a long history. It is composed of 192 traditional Chinese medicine stores represented by Ye Kaitai, Da Rentang, Liu youyutang, Jin Tongren, Jiuzhitang and Chen Taiyi, who have more than 400 years of traditional Chinese medicine history and are well-known throughout the country. In 1952, Wuhan Zhonglian pharmaceutical factory was established under the initiative of the former Wuhan herbal medicine industry association. In 1997, the joint-stock system was reformed, and the group company was established in 2002. At the end of 2011, it was reorganized into China's larger health industry platform, China Pharmaceutical Group. After more than 60 years of development and expansion, the company has formed a variety of industrial structures, including the production and sales of Chinese patent medicine, chemical preparations, pharmaceutical commercial operation, etc., and has become a professional pharmaceutical health enterprise integrating scientific research, production, circulation and foreign trade. The company focuses on the production and sales of classic Chinese medicine. There are more than 300 registered products, 82 varieties are listed in the national basic drug catalog, and 14 varieties, of which the strategic big variety Biejiajian Pill has a history of more than 2000 years. It is a classic ancient recipe of Zhang Zhongjing in Han Dynasty and specializes in treating hypochondriac diseases. The company's products are involved in the fields of liver medicine, respiratory system medicine, gynecology medicine, cardio cerebral vascular medicine, etc. it has formed a series of liver medicine represented by Biejiajian Pill, respiratory medicine represented by Jinyebaidu granule, Biyan tablet, qiangliganmao tablet, cardio cerebral vascular medicine represented by maijunan tablet and xinnaoqing soft capsule, and Jiawei biochemical granule The representative series of gynecological medicine. The company pays attention to the systematic and in-depth development of traditional Chinese medicine. Relying on the R & D platform of China Pharmaceutical Industry Research Institute under Sinopharm group, the company has extensively carried out domestic and international cooperation and exchanges, constantly explored the mechanism of classical ancient prescriptions, studied new technologies, guaranteed the product efficacy, and possessed a number of independent intellectual property rights, laying a solid foundation for the company's sustainable development. The company's marketing network covers many provinces, autonomous regions and municipalities directly under the central government, and the terminal sales outlets cover the whole country. The main products are exported to Japan, Malaysia, Indonesia, the United States and other countries and regions. The company not only sells products, but also focuses on delivering the Philosophy (Culture) and core values of traditional Chinese medicine to doctors and patients, making Zoomlion a pharmaceutical enterprise respected by doctors and patients and contributing to the development of traditional Chinese medicine in China. The "Zhonglian traditional Chinese medicine industrial park" built by the company in the Guanggu biological city of Donghu high tech Development Zone in accordance with the production standards of modern traditional Chinese medicine has been completed. In the future, the company will take this as the support, take "mining, inheriting, innovating and carrying forward Chinese traditional medicine, providing classic and good traditional Chinese medicine for" family "as the responsibility, inherit and carry forward Chinese traditional medicine, and strive to become an excellent modern Chinese medicine enterprise in China. At the end of the 13th five year plan, the operating revenue was over one billion yuan and the profit was over one billion yuan.

本文链接: https://brand.waitui.com/8764ad614.html 联系电话:027819389818805

7×24h 快讯

债市“降温” 短期内波动或仍将持续

7月以来,债基产品收益表现出现明显震荡。数据显示,截至7月12日,超1000只债基月内回报为负。多位业内人士表示,今年以来债券市场持续火热,长期债券利率下降显著。为抑制过热的市场情绪,保障市场长期稳健发展,央行于近期开展系列操作。展望后市,短期内债市波动或仍将持续,市场情绪偏向谨慎,偏防御性的中短端资产或相对占优。(中国基金报)

49分钟前

安利股份:上半年净利同比预增9348.14%—10421.8%

安利股份发布业绩预告,预计上半年净利为8800万元—9800万元,同比增长9348.14%—10421.8%。报告期内,公司主营产品销量同比增长约19.7%,销售收入同比增长约29.1%。公司主营业务发展态势良好,毛利率较上年同期实现大幅提升,利润增长。(新浪财经)

49分钟前

汇金通:半年度净利润5250万到6200万元 增加107.83%到145.43%

汇金通披露2024年半年度业绩预增公告,该公司预计报告期归属于上市公司股东的净利润为5250万元到6200万元,同比增加107.83%到145.43%。归属于上市公司股东的扣除非经常性损益的净利润为4990.53万元到5940.53万元,同比增加288.35%到362.27%。报告期内,公司持续强化成本管控,优化内部管理,积极提升运营效率,规模效益显现。主营产品产销量较上年同期有较大幅度增长,主要原材料价格较上年同期有所下降,主营产品毛利率有所回升。(新浪财经)

49分钟前

中伟股份:上半年归母净利同比预增8.04%—21.06%

中伟股份7月14日晚间发布业绩预告,预计上半年净利润11.3亿元—12.3亿元,同比增长33.76%—45.6%;归母净利润8.3亿元至9.3亿元,同比增长8.04%—21.06%。公司四大材料体系产品出货量持续保持正向增长,报告期内,镍、钴、磷、钠四系产品销售量超14万吨,同比增长15%,公司主要产品市场占有率持续保持领先。报告期内,公司印尼镍产品整体产出超3.5万金属吨,其中第二季度环比增长39%,后续随着印尼镍冶炼项目产能放量,将推动公司效益进一步提升。(新浪财经)

49分钟前

蓝晓科技:上半年净利润同比预增13.96%—18.45%

蓝晓科技7月14日晚间发布业绩预告,预计2024年半年度净利润3.94亿元—4.1亿元,同比增长13.96%—18.45%。报告期内,公司吸附分离材料销售保持良好增长,国际市场竞争力进一步提升。生命科学、提锂订单持续拓展、超纯水领域产品销售规模增加。(新浪财经)

49分钟前

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询